Sur Hydrogen Cluster study in Oman advances
At the heart of the initiative is a comprehensive plan to integrate large-scale renewables and green hydrogen production, enabling a range of industrial, petrochemical, and energy projects operating in Sur to achieve their Net Zero goals.
During its preliminary stage, the Sustainable Energy Research Centre (SERC) at Sultan Qaboos University (SQU), along with the Oman Hydrogen Alliance (Hy-Fly), assessed the technical, economic, and partnership frameworks required to position Sur as a hydrogen export and low-carbon fuel hub aligned with Oman's national energy transition ambitions.
Also participating in the initiative are Phoenix Power Oman (operator of Sur IPP), Oman India Fertilizer Company (OMIFCO), OQ Gas Networks, OQ Alternative Energy, and Madayn – the authority administering Sur Industrial City.
Sharing an update on the initiative, Oman LNG stated: 'We recently held a framing session with our key partners – Oman India Fertiliser Company SAOC (OMIFCO), OQ Gas Networks (OQGN), and OQAE – to shape the Sur Hydrogen and Energy Transition Cluster Study. We are now finalising the scope of work, which will be followed by the tendering process for a detailed feasibility study, expected to commence in the second quarter of 2025, with the Oman Energy Association (OPAL) managing the tender. This initiative is part of our broader commitment to advancing Oman's position as a leader in green hydrogen and energy transition.'
The project envisions the use of renewable energy to produce green hydrogen, which will serve as a fuel resource for project stakeholders. This shift will displace significant volumes of natural gas currently used as fuel and feedstock by Sur-based industries. The freed-up gas could then be redirected by Oman LNG for liquefaction and export. An output of around 487 tonnes per day of low-carbon hydrogen is anticipated if and when the Sur Hydrogen Cluster is fully implemented.
In addition to the cluster initiative, Oman LNG is also weighing a host of schemes to support its energy transition, energy efficiency, and decarbonisation goals.
'Key initiatives for the year include developing a FEED package for the power import project, finalising green power sourcing concepts with a robust commercial model, and conducting comprehensive assessments to enhance energy efficiency,' the majority state-owned company noted in its 2024 Sustainability Report.
Furthermore, the company has conducted a techno-economic analysis of opportunities linked to proposals such as solar photovoltaic (PV) power generation capacity, Battery Energy Storage System (BESS) capacity, and flare gas recovery. Oman LNG is working closely with OQ Alternative Energy to explore optimal renewable energy sourcing.
Additionally, a new Energy Efficiency Improvement Programme was launched this year to enhance or maintain the high thermal efficiency of Oman LNG's triple-train complex at Qalhat.
'This initiative will focus on identifying practical ways to increase efficiency and sustain our top-tier results. We are currently finalising the delivery plan for this programme, which underscores our ongoing commitment to operational excellence and responsible energy use,' the company added.
Syndigate.info).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
17 minutes ago
- Khaleej Times
UAE Central Bank revokes licence of Al Nahdi Exchange
The Central Bank of the UAE (CBUAE) has revoked the licence of Al Nahdi Exchange, an Exchange House operating in the UAE, and struck its name off the Register, pursuant to Article (137) of the Decretal Federal Law No. (14) of 2018 Regarding the Central Bank and Organisation of Financial Institutions and Activities, and its amendments. The licence revocation was based on the CBUAE's examination findings, which revealed significant failures by the Exchange House to comply with the Anti-Money Laundering, Combating the Financing of Terrorism and Illegal Organisations, and Sanctions framework. The CBUAE, through its supervisory and regulatory mandates, endeavours to ensure that all exchange houses, their owners, and staff comply with the UAE laws, regulations and standards established by the CBUAE to maintain transparency and integrity of the exchange houses industry and safeguard the UAE financial ecosystem.
Zawya
17 minutes ago
- Zawya
New agreement brings breakthrough dyslipidemia treatment to Saudi Arabia and MEA
JEDDAH – Jamjoom Pharma, a leading Saudi pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products across MEA, and Althera Laboratories, a company dedicated to developing and commercializing innovative therapies for cardiovascular and metabolic diseases, today announced a strategic licensing and supply agreement. This agreement is poised to address the growing need for effective dyslipidemia management in the region, contributing to better patient outcomes and cardiovascular health. Under this agreement, Jamjoom Pharma gets exclusive rights to commercialize in Saudi Arabia and non-exclusive rights for phased expansion across other MEA markets for Althera's fixed-dose combination of dual-action cholesterol-lowering therapy. The product launch in Saudi Arabia is targeted for 2027, with plans for phased expansion across MEA markets, subject to local regulatory approvals. This collaboration marks a major milestone for both companies: Jamjoom strengthens its cardiovascular portfolio with a globally recognized and clinically effective therapy, while Althera expands its international footprint in a high-growth region. The partnership aims to address the region's growing burden of cardiovascular diseases by increasing access to modern, affordable lipid-lowering treatment, to support patients across MEA. Dr. Tarek Hosni, CEO of Jamjoom Pharma, highlighted that: 'Cardiovascular diseases remain to be a leading health concern in Saudi Arabia and the wider MEA region, and this partnership enables us to provide patients across the MEA region with an innovative, evidence-based solution. Expanding access to effective cholesterol management aligns perfectly with our promise to deliver high-quality, affordable medications that improve lives.' Sanjeev Agarwal, CEO of Althera added " This partnership with Jamjoom Pharma is a pivotal step for Althera, allowing us to extend our reach into the rapidly growing MENA region. We are confident that Jamjoom's deep market understanding and robust capabilities make them the perfect partner to deliver our Rproduct to healthcare providers and patients in Saudi Arabia and across MENA. This collaboration is a testament to our dedication to making innovative and affordable cardiovascular treatments more accessible globally." About Althera: Founded in 2010, Althera focuses on developing, out-licensing, manufacturing and supplying high value branded and select complex generic medicines. Althera pioneers innovative value added combinations fostering benefits throughout the value chain resulting in benefits for our partners, payers, prescribers and patients particularly in heart disease, diabetes and obesity management. Althera is headquartered in Dublin, Ireland. About Jamjoom Pharma 'Jamjoom Pharmaceuticals Factory Company': Jamjoom Pharma is a leading pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products. Headquartered in Saudi Arabia, the company was established back in 2000 and is tirelessly operating to support the Saudi Vision 2030 to reinforce the public healthcare system. With a strong focus on patient-centered care, Jamjoom Pharma serves diverse markets across Middle East & Africa, with a bold ambition for more expansion, providing effective solutions in key therapeutic areas (including ophthalmology, dermatology, cardiometabolic, gastrointestinal, and general medicine). Through its state-of-the-art facilities and established distribution channels across the MEA region and dedication to regulatory excellence, Jamjoom Pharma continues to deliver products that meet the highest standards of safety, efficacy, and quality, improving health outcomes for millions of people.
Zawya
17 minutes ago
- Zawya
CBUAE revokes licence of Al Nahdi Exchange
Abu Dhabi: The Central Bank of the UAE (CBUAE) has revoked the licence of Al Nahdi Exchange, an Exchange House operating in the UAE, and struck its name off the Register, pursuant to Article (137) of the Decretal Federal Law No. (14) of 2018 Regarding the Central Bank and Organization of Financial Institutions and Activities, and its amendments. The licence revocation was imposed based on the results of the findings of examinations conducted by the CBUAE, which revealed that the Exchange House had significant failures to comply with the Anti-Money Laundering and Combating the Financing of Terrorism and Illegal Organisations and Sanctions framework. The CBUAE, through its supervisory and regulatory mandates, endeavours to ensure that all exchange houses, their owners, and staff comply with the UAE laws, regulations and standards established by the CBUAE to maintain transparency and integrity of the exchange houses industry and safeguard the UAE financial ecosystem.
